Free Trial
NASDAQ:GNPX

Genprex (GNPX) Stock Price, News & Analysis

Genprex logo
$2.15
-0.10 (-4.44%)
(As of 11/1/2024 ET)

About Genprex Stock (NASDAQ:GNPX)

Key Stats

Today's Range
$2.00
$2.59
50-Day Range
$0.33
$3.59
52-Week Range
$0.28
$14.80
Volume
4.08 million shs
Average Volume
2.78 million shs
Market Capitalization
$5.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
87th Percentile Overall Score

GNPX MarketRank™: 

Genprex scored higher than 87% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genprex has received no research coverage in the past 90 days.

  • Read more about Genprex's stock forecast and price target.
  • Earnings Growth

    Earnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.

  • Price to Book Value per Share Ratio

    Genprex has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Genprex's valuation and earnings.
  • Percentage of Shares Shorted

    3.51% of the float of Genprex has been sold short.
  • Short Interest Ratio / Days to Cover

    Genprex has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genprex has recently increased by 5.19%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Genprex does not currently pay a dividend.

  • Dividend Growth

    Genprex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.51% of the float of Genprex has been sold short.
  • Short Interest Ratio / Days to Cover

    Genprex has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genprex has recently increased by 5.19%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Genprex has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Genprex this week, compared to 1 article on an average week.
  • Search Interest

    14 people have searched for GNPX on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Genprex to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genprex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.47% of the stock of Genprex is held by insiders.

  • Percentage Held by Institutions

    Only 14.05% of the stock of Genprex is held by institutions.

  • Read more about Genprex's insider trading history.
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

GNPX Stock News Headlines

Genprex to Participate in 2024 BIO Europe Conference
Looking Into Genprex's Recent Short Interest
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Genprex advances dose in lung cancer trial
See More Headlines

GNPX Stock Analysis - Frequently Asked Questions

Genprex's stock was trading at $9.20 on January 1st, 2024. Since then, GNPX shares have decreased by 76.6% and is now trading at $2.15.
View the best growth stocks for 2024 here
.

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Friday, August, 9th. The company reported ($3.00) earnings per share for the quarter, missing analysts' consensus estimates of ($2.30) by $0.70.

Shares of Genprex reverse split on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/09/2024
Today
11/02/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+365.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-30,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.99 per share

Miscellaneous

Free Float
2,370,000
Market Cap
$5.57 million
Optionable
No Data
Beta
-0.59
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:GNPX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners